Incidence, Patient Characteristics, Mode of Drug Delivery, and Outcomes of Septic Shock Patients Treated With Vasopressors in the Arise Trial
Andrew A Udy, Mark Finnis, Daryl Jones, Anthony Delaney, Stephen Macdonald, Rinaldo Bellomo, Sandra Peake, V Bennett, J Board, P McCracken, S McGloughlin, V Nanjayya, A Teo, E Hill, P Jones, E O'Brien, F Sawtell, K Schimanski, D Wilson, R Bellomo Show all
SHOCK | LIPPINCOTT WILLIAMS & WILKINS | Published : 2019
INTRODUCTION: To describe the utilization of vasopressors (VP) in patients enrolled in the Australasian Resuscitation In Sepsis Evaluation (ARISE) trial, and to explore the association between time to VP and 90-day mortality. METHODS: The primary exposure variable was VP use after arrival in the emergency department (ED). Vasoactive agents considered as VP included: norepinephrine, epinephrine, metaraminol, or vasopressin. Time-to-event analysis, multivariable logistic regression, and propensity-matched treatment effects modeling were used to assess the association between time to VP and 90-day mortality. RESULTS: In total 1,102 of 1,588 patients (69%) in ARISE received VP at any point. The ..View full abstract
Awarded by National Health and Medical Research Council of Australia
The ARISE EGDT Trial was supported by grants from the National Health and Medical Research Council of Australia (GNT491075 and GNT1021165) and the Alfred Foundation.